                         SEQUENCE LISTING

<110>  PROBIODRUG AG
 
<120>  IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS

<130>  PBD00083/WO

<160>  6     

<170>  PatentIn version 3.5

<210>  1
<211>  382
<212>  PRT
<213>  Human

<400>  1

Met Arg Ser Gly Gly Arg Gly Arg Pro Arg Leu Arg Leu Gly Glu Arg 
1               5                   10                  15      


Gly Leu Met Glu Pro Leu Leu Pro Pro Lys Arg Arg Leu Leu Pro Arg 
            20                  25                  30          


Val Arg Leu Leu Pro Leu Leu Leu Ala Leu Ala Val Gly Ser Ala Phe 
        35                  40                  45              


Tyr Thr Ile Trp Ser Gly Trp His Arg Arg Thr Glu Glu Leu Pro Leu 
    50                  55                  60                  


Gly Arg Glu Leu Arg Val Pro Leu Ile Gly Ser Leu Pro Glu Ala Arg 
65                  70                  75                  80  


Leu Arg Arg Val Val Gly Gln Leu Asp Pro Gln Arg Leu Trp Ser Thr 
                85                  90                  95      


Tyr Leu Arg Pro Leu Leu Val Val Arg Thr Pro Gly Ser Pro Gly Asn 
            100                 105                 110         


Leu Gln Val Arg Lys Phe Leu Glu Ala Thr Leu Arg Ser Leu Thr Ala 
        115                 120                 125             


Gly Trp His Val Glu Leu Asp Pro Phe Thr Ala Ser Thr Pro Leu Gly 
    130                 135                 140                 


Pro Val Asp Phe Gly Asn Val Val Ala Thr Leu Asp Pro Arg Ala Ala 
145                 150                 155                 160 


Arg His Leu Thr Leu Ala Cys His Tyr Asp Ser Lys Leu Phe Pro Pro 
                165                 170                 175     


Gly Ser Thr Pro Phe Val Gly Ala Thr Asp Ser Ala Val Pro Cys Ala 
            180                 185                 190         


Leu Leu Leu Glu Leu Ala Gln Ala Leu Asp Leu Glu Leu Ser Arg Ala 
        195                 200                 205             


Lys Lys Gln Ala Ala Pro Val Thr Leu Gln Leu Leu Phe Leu Asp Gly 
    210                 215                 220                 


Glu Glu Ala Leu Lys Glu Trp Gly Pro Lys Asp Ser Leu Tyr Gly Ser 
225                 230                 235                 240 


Arg His Leu Ala Gln Leu Met Glu Ser Ile Pro His Ser Pro Gly Pro 
                245                 250                 255     


Thr Arg Ile Gln Ala Ile Glu Leu Phe Met Leu Leu Asp Leu Leu Gly 
            260                 265                 270         


Ala Pro Asn Pro Thr Phe Tyr Ser His Phe Pro Arg Thr Val Arg Trp 
        275                 280                 285             


Phe His Arg Leu Arg Ser Ile Glu Lys Arg Leu His Arg Leu Asn Leu 
    290                 295                 300                 


Leu Gln Ser His Pro Gln Glu Val Met Tyr Phe Gln Pro Gly Glu Pro 
305                 310                 315                 320 


Phe Gly Ser Val Glu Asp Asp His Ile Pro Phe Leu Arg Arg Gly Val 
                325                 330                 335     


Pro Val Leu His Leu Ile Ser Thr Pro Phe Pro Ala Val Trp His Thr 
            340                 345                 350         


Pro Ala Asp Thr Glu Val Asn Leu His Pro Pro Thr Val His Asn Leu 
        355                 360                 365             


Cys Arg Ile Leu Ala Val Phe Leu Ala Glu Tyr Leu Gly Leu 
    370                 375                 380         


<210>  2
<211>  1149
<212>  DNA
<213>  Human

<400>  2
atgcgttccg ggggccgcgg gcgaccccgc ctgcggctgg gggaacgtgg cctcatggag       60

ccactcttgc cgccgaagcg ccgcctgcta ccgcgggttc ggctcttgcc tctgttgctg      120

gcgctggccg tgggctcggc gttctacacc atttggagcg gctggcaccg caggactgag      180

gagctgccgc tgggccggga gctgcgggtc ccattgatcg gaagcctccc cgaagcccgg      240

ctgcggaggg tggtgggaca actggatcca cagcgtctct ggagcactta tctgcgcccc      300

ctgctggttg tgcgaacccc gggcagcccg ggaaatctcc aagtcagaaa gttcctggag      360

gccacgctgc ggtccctgac agcaggttgg cacgtggagc tggatccctt cacagcctca      420

acacccctgg ggccagtgga ctttggcaat gtggtggcca cactggaccc aagggctgcc      480

cgtcacctca cccttgcctg ccattatgac tcgaagctct tcccacccgg atcgaccccc      540

tttgtagggg ccacggattc ggctgtgccc tgtgccctgc tgctggagct ggcccaagca      600

cttgacctgg agctgagcag ggccaaaaaa caggcagccc cggtgaccct gcaactgctc      660

ttcttggatg gtgaagaggc gctgaaggag tggggaccca aggactccct ttacggttcc      720

cggcacctgg cccagctcat ggagtctata cctcacagcc ccggccccac caggatccag      780

gctattgagc tctttatgct tcttgatctc ctgggagccc ccaatcccac cttctacagc      840

cacttccctc gcacggtccg ctggttccat cggctgagga gcattgagaa gcgtctgcac      900

cgtttgaacc tgctgcagtc tcatccccag gaagtgatgt acttccaacc cggggagccc      960

tctggctctg tggaagacga ccacatcccc ttcctccgca gaggggtacc cgtgctccat     1020

ctcatctcca cgcccttccc tgctgtctgg cacacccctg cggacaccga ggtcaatctc     1080

cacccaccca cggtacacaa cttgtgccgc attctcgctg tgttcctggc tgaatacctg     1140

gggctctag                                                             1149


<210>  3
<211>  19
<212>  DNA
<213>  Synthetic Primer

<400>  3
ctcggcgttc tacaccatt                                                    19


<210>  4
<211>  18
<212>  DNA
<213>  Synthetic Primer

<400>  4
ctgctcagct ccaggtca                                                     18


<210>  5
<211>  28
<212>  DNA
<213>  Synthetic Primer

<400>  5
ctacaactgg tcagcctgac tactaacc                                          28


<210>  6
<211>  25
<212>  DNA
<213>  Synthetic Primer

<400>  6
tgatccagga atctaaggca gcacc                                             25


